EX-99.3 4 ex99312312019.htm EXHIBIT 99.3 Exhibit



Exhibit 99.3
 
healthpeaklogohorizblkrgba01.jpg  
 
 

Discussion and

Reconciliation of Non-

GAAP Financial Measures
 
December 31, 2019
 
 
 
 
 
(Unaudited)



Definitions

Adjusted Fixed Charge Coverage  Adjusted EBITDAre divided by Fixed Charges. Adjusted Fixed Charge Coverage is a supplemental measure of liquidity and our ability to meet interest payments on our outstanding debt and pay dividends to our preferred stockholders, if applicable. Our various debt agreements contain covenants that require us to maintain ratios similar to Adjusted Fixed Charge Coverage and credit rating agencies utilize similar ratios in evaluating and determining the credit rating on certain of our debt instruments. Adjusted Fixed Charge Coverage is subject to the same limitations and qualifications as Adjusted EBITDAre and Fixed Charges.
Cash Operating Expenses Cash Operating Expenses represent property level operating expenses (which exclude transition costs) after eliminating the effects of straight-line rents, lease termination fees, actuarial reserves for insurance claims that have been incurred but not reported, and the impact of deferred community fee expense.
Cash Real Estate Revenues Cash Real Estate Revenues represent rental and related revenues, resident fees and services, and income from DFLs after eliminating the effects of straight-line rents, DFL non-cash interest, amortization of market lease intangibles, lease termination fees, and the impact of deferred community fee income.
Consolidated Debt The carrying amount of bank line of credit, commercial paper, term loans, senior unsecured notes, mortgage debt, and other debt, as reported in our consolidated financial statements.
Consolidated Gross Assets The carrying amount of total assets, excluding investments in and advances to our unconsolidated JVs, after adding back accumulated depreciation and amortization, as reported in our consolidated financial statements. Consolidated Gross Assets is a supplemental measure of our financial position, which, when used in conjunction with debt-related measures, enables both management and investors to analyze our leverage and to compare our leverage to that of other companies.
Consolidated Secured Debt Mortgage and other debt secured by real estate, as reported in our consolidated financial statements.
Debt Investments Loans secured by a direct interest in real estate and mezzanine loans.
Direct Financing Lease ("DFL") Lease for which future minimum lease payments are recorded as a receivable and the difference between the future minimum lease payments and the estimated residual values less the cost of the properties is recorded as unearned income. Unearned income is deferred and amortized to income over the lease terms to provide a constant yield.
EBITDAre and Adjusted EBITDAre EBITDAre, or EBITDA for Real Estate, is a supplemental performance measure defined by the National Association of Real Estate Investment Trusts (“NAREIT”) and intended for real estate companies. It represents earnings before interest expense, income taxes, depreciation and amortization, gains or losses from sales of depreciable property (including gains or losses on change in control), and impairment charges (recoveries) related to depreciable property. Adjusted EBITDAre is defined as EBITDAre excluding impairments (recoveries) related to non-depreciable assets, transaction-related items, prepayment costs (benefits) associated with early retirement or payment of debt, severance and related charges, litigation costs (recoveries), casualty-related charges (recoveries), stock compensation expense, and foreign currency remeasurement losses (gains), and is adjusted to include our share of CCRC non-refundable entrance fees received. EBITDAre and Adjusted EBITDAre include our pro rata share of our unconsolidated JVs presented on the same basis. We consider EBITDAre and Adjusted EBITDAre important supplemental measures to net income (loss) because they provide an additional manner in which to evaluate our operating performance and serve as additional indicators of our ability service our debt obligations. Net income (loss) is the most directly comparable U.S. generally accepted accounting principles (“GAAP”) measure to EBITDAre and Adjusted EBITDAre.
Enterprise Debt Consolidated Debt plus our pro rata share of total debt from our unconsolidated JVs. Enterprise Debt is a supplemental measure of our financial position, which enables both management and investors to analyze our leverage and to compare our leverage to that of other companies. Our pro rata share information is calculated by applying our actual ownership percentage for the period and excludes debt funded by us to our JVs. Our pro rata share of total debt from our unconsolidated JVs is not intended to reflect our actual liability or ability to access assets should there be a default under any or all such loans or a liquidation of the JVs.
Enterprise Gross Assets Consolidated Gross Assets plus our pro rata share of total gross assets from our unconsolidated JVs, after adding back accumulated depreciation and amortization. Enterprise Gross Assets is a supplemental measure of our financial position, which, when used in conjunction with debt-related measures, enables both management and investors to analyze our leverage and to compare our leverage to that of other companies.
Enterprise Secured Debt Consolidated Secured Debt plus our pro rata share of mortgage debt from our unconsolidated JVs. Enterprise Secured Debt is a supplemental measure of our financial position, which enables both management and investors to analyze our leverage and to compare our leverage to that of other companies. Our pro rata share of Enterprise Secured Debt from our unconsolidated JVs is not intended to reflect our actual liability or ability to access assets should there be a default under any or all such loans or a liquidation of the JVs.

healthpeaklogohorizblkrgba01.jpg
2

Definitions

Entrance Fee Certain of our communities have residency agreements which require the resident to pay an upfront entrance fee prior to taking occupancy at the community. For net income, NOI and NAREIT FFO, the non-refundable portion of the entrance fee is recorded as deferred entrance fee revenue and amortized over the estimated stay of the resident based on an actuarial valuation. For Cash NOI and FAD, the non-refundable entrance fees ("NREFs") are recognized upon receipt, net of a reserve for statutory refunds due to early terminations. The refundable portion of a resident’s entrance fee is generally refundable within a certain number of months or days following contract termination or upon the sale of the unit. All refundable amounts due to residents at any time in the future are classified as liabilities.
Financial Leverage Enterprise Debt divided by Enterprise Gross Assets. Financial Leverage is a supplemental measure of our financial position, which enables both management and investors to analyze our leverage and to compare our leverage to that of other companies. Our pro rata share information is calculated by applying our actual ownership percentage for the period and excludes debt funded by us to our JVs. Our pro rata share of total debt from our unconsolidated JVs is not intended to reflect our actual liability or ability to access assets should there be a default under any or all such loans or a liquidation of the JVs.
Fixed Charges Total interest expense plus capitalized interest plus preferred stock dividends (if applicable). Fixed Charges also includes our pro rata share of the interest expense plus capitalized interest plus preferred stock dividends (if applicable) of our unconsolidated JVs. Fixed Charges is a supplemental measure of our interest payments on outstanding debt and dividends to preferred stockholders for purposes of presenting Fixed Charge Coverage and Adjusted Fixed Charge Coverage. Fixed Charges is subject to limitations and qualifications, as, among other things, it does not include all contractual obligations.
Funds Available for Distribution (“FAD”) FAD is defined as FFO as Adjusted after excluding the impact of the following: (i) amortization of deferred compensation expense, (ii) amortization of deferred financing costs, net, (iii) straight-line rents, (iv) deferred income taxes, (v) amortization of acquired market lease intangibles, net, (vi) non-cash interest related to DFLs and lease incentive amortization (reduction of straight-line rents), (vii) actuarial reserves for insurance claims that have been incurred but not reported, and (viii) deferred revenues, excluding amounts amortized into rental income that are associated with tenant funded improvements owned/recognized by us and up-front cash payments made by tenants to reduce their contractual rents. Also, FAD: (i) is computed after deducting recurring capital expenditures, including second generation leasing costs and second generation tenant and capital improvements and (ii) includes lease restructure payments and adjustments to compute our share of FAD from our unconsolidated joint ventures and those related to CCRC non-refundable entrance fees. Certain prior period amounts in the “Non-GAAP Financial Measures Reconciliation” below for FAD have been reclassified to conform to the current period presentation. More specifically, recurring capital expenditures, including second generation leasing costs and second generation tenant and capital improvements ("FAD capital expenditures") excludes our share from unconsolidated joint ventures (reported in “other FAD adjustments”). Adjustments for joint ventures are calculated to reflect our pro-rata share of both our consolidated and unconsolidated joint ventures. We reflect our share of FAD for unconsolidated joint ventures by applying our actual ownership percentage for the period to the applicable reconciling items on an entity by entity basis. We reflect our share for consolidated joint ventures in which we do not own 100% of the equity by adjusting our FAD to remove the third party ownership share of the applicable reconciling items based on actual ownership percentage for the applicable periods (reported in “other FAD adjustments”). See FFO for further disclosure regarding our use of pro-rata share information and its limitations. Other REITs or real estate companies may use different methodologies for calculating FAD, and accordingly, our FAD may not be comparable to those reported by other REITs. Although our FAD computation may not be comparable to that of other REITs, management believes FAD provides a meaningful supplemental measure of our performance and is frequently used by analysts, investors, and other interested parties in the evaluation of our performance as a REIT. We believe FAD is an alternative run-rate earnings measure that improves the understanding of our operating results among investors and makes comparisons with: (i) expected results, (ii) results of previous periods, and (iii) results among REITs more meaningful. FAD does not represent cash generated from operating activities determined in accordance with GAAP and is not necessarily indicative of cash available to fund cash needs as it excludes the following items which generally flow through our cash flows from operating activities: (i) adjustments for changes in working capital or the actual timing of the payment of income or expense items that are accrued in the period, (ii) transaction-related costs, (iii) litigation settlement expenses, (iv) severance-related expenses, and (v) actual cash receipts from interest income recognized on loans receivable (in contrast to our FAD adjustment to exclude non-cash interest and depreciation related to our investments in direct financing leases). Furthermore, FAD is adjusted for recurring capital expenditures, which are generally not considered when determining cash flows from operations or liquidity. FAD is a non-GAAP supplemental financial measure and should not be considered as an alternative to net income (loss) determined in accordance with GAAP.
Funds From Operations (“FFO”) FFO encompasses NAREIT FFO and FFO as Adjusted, each of which is described in detail below. We believe FFO applicable to common shares, diluted FFO applicable to common shares, and diluted FFO per common share are important supplemental non-GAAP measures of operating performance for a REIT. Because the historical cost accounting convention used for real estate assets utilizes straight-line depreciation (except on land), such accounting presentation implies that the value of real estate assets diminishes predictably over time. Since real estate values instead have historically risen and fallen with market conditions, presentations of operating results for a REIT that use historical cost accounting for depreciation could be less informative. The term FFO was designed by the REIT industry to address this issue.
NAREIT FFO. FFO, as defined by the National Association of Real Estate Investment Trusts (“NAREIT”), is net income (loss) applicable to common shares (computed in accordance with GAAP), excluding gains or losses from sales of depreciable property, including any current and deferred taxes directly associated with sales of depreciable property, impairments of, or related to, depreciable real estate, plus real estate and other real estate-related depreciation and amortization, and adjustments to compute

healthpeaklogohorizblkrgba01.jpg
3

Definitions

our share of NAREIT FFO and FFO as Adjusted (see below) from joint ventures. Adjustments for joint ventures are calculated to reflect our pro-rata share of both our consolidated and unconsolidated joint ventures. We reflect our share of NAREIT FFO for unconsolidated joint ventures by applying our actual ownership percentage for the period to the applicable reconciling items on an entity by entity basis. For consolidated joint ventures in which we do not own 100%, we reflect our share of the equity by adjusting our NAREIT FFO to remove the third party ownership share of the applicable reconciling items based on actual ownership percentage for the applicable periods. Our pro-rata share information is prepared on a basis consistent with the comparable consolidated amounts, is intended to reflect our proportionate economic interest in the operating results of properties in our portfolio and is calculated by applying our actual ownership percentage for the period. We do not control the unconsolidated joint ventures, and the pro-rata presentations of reconciling items included in NAREIT FFO do not represent our legal claim to such items. The joint venture members or partners are entitled to profit or loss allocations and distributions of cash flows according to the joint venture agreements, which provide for such allocations generally according to their invested capital.
The presentation of pro-rata information has limitations, which include, but are not limited to, the following: (i) the amounts shown on the individual line items were derived by applying our overall economic ownership interest percentage determined when applying the equity method of accounting and do not necessarily represent our legal claim to the assets and liabilities, or the revenues and expenses and (ii) other companies in our industry may calculate their pro-rata interest differently, limiting the usefulness as a comparative measure. Because of these limitations, the pro-rata financial information should not be considered independently or as a substitute for our financial statements as reported under GAAP. We compensate for these limitations by relying primarily on our GAAP financial statements, using the pro-rata financial information as a supplement.
NAREIT FFO does not represent cash generated from operating activities in accordance with GAAP, is not necessarily indicative of cash available to fund cash needs and should not be considered an alternative to net income (loss). We compute NAREIT FFO in accordance with the current NAREIT definition; however, other REITs may report NAREIT FFO differently or have a different interpretation of the current NAREIT definition from ours.
FFO as Adjusted. In addition, we present NAREIT FFO on an adjusted basis before the impact of non-comparable items including, but not limited to, transaction-related items, impairments (recoveries) of non-depreciable assets, losses (gains) from the sale of non-depreciable assets, severance and related charges, prepayment costs (benefits) associated with early retirement or payment of debt, litigation costs (recoveries), casualty-related charges (recoveries), foreign currency remeasurement losses (gains), and changes in tax legislation (“FFO as Adjusted”). Transaction-related items include transaction expenses and gains/charges incurred as a result of mergers and acquisitions and lease amendment or termination activities. Prepayment costs (benefits) associated with early retirement of debt include the write-off of unamortized deferred financing fees, or additional costs, expenses, discounts, make-whole payments, penalties or premiums incurred as a result of early retirement or payment of debt. Management believes that FFO as Adjusted provides a meaningful supplemental measurement of our FFO run-rate and is frequently used by analysts, investors, and other interested parties in the evaluation of our performance as a REIT. At the same time that NAREIT created and defined its FFO measure for the REIT industry, it also recognized that “management of each of its member companies has the responsibility and authority to publish financial information that it regards as useful to the financial community.” We believe stockholders, potential investors, and financial analysts who review our operating performance are best served by an FFO run-rate earnings measure that includes certain other adjustments to net income (loss), in addition to adjustments made to arrive at the NAREIT defined measure of FFO. FFO as Adjusted is used by management in analyzing our business and the performance of our properties and we believe it is important that stockholders, potential investors, and financial analysts understand this measure used by management. We use FFO as Adjusted to: (i) evaluate our performance in comparison with expected results and results of previous periods, relative to resource allocation decisions, (ii) evaluate the performance of our management, (iii) budget and forecast future results to assist in the allocation of resources, (iv) assess our performance as compared with similar real estate companies and the industry in general, and (v) evaluate how a specific potential investment will impact our future results. Other REITs or real estate companies may use different methodologies for calculating an adjusted FFO measure, and accordingly, our FFO as Adjusted may not be comparable to those reported by other REITs.
Investment and Portfolio Investment Represents: (i) the carrying amount of real estate assets and intangibles, after adding back accumulated depreciation and amortization and (ii) the carrying amount of DFLs and Debt Investments. Portfolio Investment also includes our pro rata share of the real estate assets and intangibles held in our unconsolidated JVs, presented on the same basis as Investment, less the value attributable to refundable Entrance Fee liabilities. Investment and Portfolio Investment exclude land held for development.
Net Debt Enterprise Debt less the carrying amount of cash and cash equivalents as reported in our consolidated financial statements and our pro rata share of cash and cash equivalents from our unconsolidated JVs. Consolidated Debt is the most directly comparable GAAP measure to Net Debt. Net Debt is a supplemental measure of our financial position, which enables both management and investors to analyze our leverage and to compare our leverage to that of other companies.
Net Debt to Adjusted EBITDAre Net Debt divided by Adjusted EBITDAre is a supplemental measure of our ability to decrease our debt. Because we may not be able to use our cash to reduce our debt on a dollar-for-dollar basis, this measure may have material limitations.

healthpeaklogohorizblkrgba01.jpg
4

Definitions

Net Operating Income from Continuing Operations (“NOI”) and Cash NOI NOI and Adjusted NOI are non-U.S. generally accepted accounting principles (“GAAP”) supplemental financial measures used to evaluate the operating performance of real estate. NOI is defined as real estate revenues (inclusive of rental and related revenues, resident fees and services, and income from direct financing leases), less property level operating expenses (which exclude transition costs); NOI excludes all other financial statement amounts included in net income (loss). Management believes NOI provides relevant and useful information because it reflects only income and operating expense items that are incurred at the property level and presents them on an unlevered basis. Adjusted NOI is calculated as NOI after eliminating the effects of straight-line rents, DFL non-cash interest, amortization of market lease intangibles, termination fees, actuarial reserves for insurance claims that have been incurred but not reported, and the impact of deferred community fee income and expense. Adjusted NOI is oftentimes referred to as “Cash NOI.” NOI and Adjusted NOI exclude our share of income (loss) generated by unconsolidated joint ventures, which is recognized in equity income (loss) from unconsolidated joint ventures in the consolidated statements of operations. We use NOI and Adjusted NOI to make decisions about resource allocations, to assess and compare property level performance, and to evaluate our same property portfolio (“SPP”), as described below. We believe that net income (loss) is the most directly comparable GAAP measure to NOI and Adjusted NOI. NOI and Adjusted NOI should not be viewed as alternative measures of operating performance to net income (loss) as defined by GAAP since they do not reflect various excluded items. Further, our definitions of NOI and Adjusted NOI may not be comparable to the definitions used by other REITs or real estate companies, as they may use different methodologies for calculating NOI and Adjusted NOI.
Operating expenses generally relate to leased medical office and life science properties and SHOP facilities. We generally recover all or a portion of our leased medical office and life science property expenses through tenant recoveries. We present expenses as operating or general and administrative based on the underlying nature of the expense.
Portfolio Income Cash NOI plus interest income plus our pro rata share of Cash NOI from our unconsolidated JVs.
Real Estate Revenues Real Estate Revenues include rental related revenues, tenant recoveries, resident fees and services and income from DFLs.
Revenue Per Occupied Room ("REVPOR") SHOP The 3-month average Cash Real Estate Revenues per occupied unit for the most recent period available. REVPOR SHOP excludes newly completed assets under lease-up, assets sold, acquired or transitioned to a new operating structure (such as triple-net to SHOP) during the relevant period, assets in redevelopment, assets that are held for sale, and assets that experienced a casualty event that significantly impacted operations. REVPOR SHOP is a non-GAAP supplemental financial measure used to evaluate the revenue-generating capacity and profit potential of our SHOP assets independent of fluctuating occupancy rates. It is also used in comparison against industry and competitor statistics, if known, to evaluate the quality of our SHOP assets.
RIDEA A structure whereby a taxable REIT subsidiary is permitted to rent a healthcare facility from its parent REIT and hire an independent contractor to operate the facility.
Same Property Portfolio SPP NOI and Adjusted (Cash) NOI information allows us to evaluate the performance of our property portfolio under a consistent population by eliminating changes in the composition of our consolidated portfolio of properties. SPP NOI excludes certain non-property specific operating expenses that are allocated to each operating segment on a consolidated basis.
Properties are included in SPP once they are stabilized for the full period in both comparison periods. Newly acquired operating assets are generally considered stabilized at the earlier of lease-up (typically when the tenant(s) control(s) the physical use of at least 80% of the space) or 12 months from the acquisition date. Newly completed developments and redevelopments are considered stabilized at the earlier of lease-up or 24 months from the date the property is placed in service. Properties that experience a change in reporting structure, such as a transition from a triple-net lease to a RIDEA reporting structure, are considered stabilized after 12 months in operations under a consistent reporting structure. A property is removed from SPP when it is classified as held for sale, sold, placed into redevelopment, experiences a casualty event that significantly impacts operations or a change in reporting structure has been agreed to (such as triple-net to SHOP).
Secured Debt Ratio Enterprise Secured Debt divided by Enterprise Gross Assets. Secured Debt Ratio is a supplemental measure of our financial position, which enables both management and investors to analyze our leverage and to compare our leverage to that of other companies. Our pro rata share information is calculated by applying our actual ownership percentage for the period and excludes debt funded by us to our JVs. Our pro rata share of Total Secured Debt from our unconsolidated JVs is not intended to reflect our actual liability or ability to access assets should there be a default under any or all such loans or a liquidation of the JVs.
Segments Our portfolio is comprised of investments in the following healthcare segments: (i) senior housing triple-net, (ii) senior housing operating portfolio (“SHOP”), (iii) life science (iv) medical office, and (v) other non-reportable segments (“Other”).
Share of Unconsolidated Joint Ventures ("JVs") Our pro rata share information is prepared on a basis consistent with the comparable consolidated amounts by applying our actual ownership percentage for the period and is intended to reflect our proportionate economic interest in the financial position and operating results of properties in our portfolio.


healthpeaklogohorizblkrgba01.jpg
5

Reconciliations
In thousands, except for per share data

Funds From Operations
 
Three Months Ended December 31,
 
Year Ended
December 31,
 
2019
 
2018
 
2019
 
2018
Net income (loss) applicable to common shares
$
43,200

 
$
829,325

 
$
43,987

 
$
1,058,424

Real estate related depreciation and amortization
190,798

 
130,759

 
659,989

 
549,499

Healthpeak's share of real estate related depreciation and amortization from unconsolidated joint ventures
15,151

 
15,237

 
60,303

 
63,967

Noncontrolling interests' share of real estate related depreciation and amortization
(5,128
)
 
(3,828
)
 
(20,054
)
 
(11,795
)
Other real estate-related depreciation and amortization
1,357

 
2,071

 
6,155

 
6,977

Loss (gain) on sales of real estate, net
(4,193
)
 
(763,774
)
 
(22,900
)
 
(925,985
)
Healthpeak's share of loss (gain) on sales of real estate, net, from unconsolidated joint ventures
(2,118
)
 

 
(2,118
)
 

Noncontrolling interests' share of gain (loss) on sales of real estate, net
129

 

 
335

 

Loss (gain) upon change of control, net(1)
(155,225
)
 
(50,171
)
 
(166,707
)
 
(9,154
)
Taxes associated with real estate dispositions

 
2,765

 

 
3,913

Impairments (recoveries) of depreciable real estate, net(2)
110,284

 
32,803

 
221,317

 
44,343

NAREIT FFO applicable to common shares
194,255

 
195,187

 
780,307

 
780,189

Distributions on dilutive convertible units and other
1,637

 

 
6,592

 

Diluted NAREIT FFO applicable to common shares
$
195,892

 
$
195,187

 
$
786,899

 
$
780,189

 
 
 
 
 
 
 
 
Weighted average shares outstanding - diluted NAREIT FFO
506,017

 
473,289

 
494,335

 
470,719

 
 
 
 
 
 
 
 
Impact of adjustments to NAREIT FFO:


 


 
 
 
 
Transaction-related items
$
1,688

 
$
2,416

 
$
15,347

 
$
11,029

Other impairments (recoveries) and losses (gains), net(3)

 
3,277

 
10,147

 
7,619

Severance and related charges(4)

 
595

 
5,063

 
13,906

Loss on debt extinguishments(5)
22,213

 
263

 
58,364

 
44,162

Litigation costs (recoveries)
29

 
323

 
(520
)
 
363

Casualty-related charges (recoveries), net(6)
530

 

 
(4,106
)
 

Foreign currency remeasurement losses (gains)
100

 
72

 
(250
)
 
(35
)
Total adjustments
24,560

 
6,946

 
84,045

 
77,044

FFO as Adjusted applicable to common shares
218,815

 
202,133

 
864,352

 
857,233

Distributions on dilutive convertible units and other
1,585

 
(18
)
 
6,396

 
(198
)
Diluted FFO as Adjusted applicable to common shares
$
220,400

 
$
202,115

 
$
870,748

 
$
857,035

 
 
 
 
 
 
 
 
Weighted average shares outstanding - diluted FFO as Adjusted
506,017

 
473,289

 
494,335

 
470,719

 
 
 
 
 
 
 
 
Diluted earnings per common share
$
0.09

 
$
1.73

 
$
0.09

 
$
2.24

Depreciation and amortization
0.40

 
0.31

 
1.43

 
1.30

Loss (gain) on sales of real estate, net
(0.01
)
 
(1.61
)
 
(0.04
)
 
(1.96
)
Loss (gain) upon change of control, net(1)
(0.31
)
 
(0.10
)
 
(0.34
)
 
(0.02
)
Taxes associated with real estate dispositions

 
0.01

 

 
0.01

Impairments (recoveries) of depreciable real estate, net(2)
0.22

 
0.07

 
0.45

 
0.09

Diluted NAREIT FFO per common share
$
0.39

 
$
0.41

 
$
1.59

 
$
1.66

Transaction-related items

 
0.01

 
0.03

 
0.02

Other impairments (recoveries) and losses (gains), net(3)

 
0.01

 
0.02

 
0.02

Severance and related charges(4)

 

 
0.01

 
0.03

Loss on debt extinguishments(5)
0.05

 

 
0.12

 
0.09

Casualty-related charges (recoveries), net(6)

 

 
(0.01
)
 

Diluted FFO as Adjusted per common share
$
0.44

 
$
0.43

 
$
1.76

 
$
1.82


healthpeaklogohorizblkrgba01.jpg
6

Reconciliations
In thousands


Funds Available for Distribution
 
Three Months Ended December 31,
 
Year Ended
December 31,
 
2019
 
2018
 
2019
 
2018
FFO as Adjusted applicable to common shares
$
218,815

 
$
202,133

 
$
864,352

 
$
857,233

Amortization of deferred compensation(7)
3,177

 
3,465

 
14,790

 
14,714

Amortization of deferred financing costs
2,689

 
2,851

 
10,863

 
12,612

Straight-line rents
(6,259
)
 
(2,251
)
 
(28,451
)
 
(23,138
)
FAD capital expenditures
(46,004
)
 
(35,956
)
 
(108,844
)
 
(106,193
)
Lease restructure payments
284

 
294

 
1,153

 
1,195

CCRC entrance fees(8)
4,785

 
4,677

 
18,856

 
17,880

Deferred income taxes
(4,909
)
 
(5,993
)
 
(18,972
)
 
(18,744
)
Other FAD adjustments(9)
(3,574
)
 
(1,219
)
 
(7,927
)
 
(9,162
)
FAD applicable to common shares
169,004

 
168,001

 
745,820

 
746,397

Distributions on dilutive convertible units and other
1,637

 

 
6,591

 

Diluted FAD applicable to common shares
$
170,641

 
$
168,001

 
$
752,411

 
$
746,397

 
 
 
 
 
 
 
 
Weighted average shares outstanding - diluted FAD
506,017

 
473,289

 
494,335

 
470,719

______________________________________
(1)
For the three months ended December 31, 2019, primarily relates to the gain related to the deconsolidation of 19 previously consolidated senior housing assets that were contributed into a new unconsolidated joint venture (Sovereign Wealth Fund Senior Housing JV). For the year ended December 31, 2019, also includes the gain related to the acquisition of the outstanding equity interests in a previously unconsolidated senior housing joint venture (Vintage Park). For the three months ended December 31, 2018, represents the gain related to the acquisition of our partner's interests in four previously unconsolidated life science assets. For the year ended December 31, 2018, also includes the loss on consolidation of seven U.K. care homes.
(2)
For the year ended December 31, 2019, includes a $6 million impairment charge related to depreciable real estate held by the CCRC JV, which we recognized in equity income (loss) from unconsolidated joint ventures in the consolidated statement of operations.
(3)
For the year ended December 31, 2019, represents the impairment of 13 senior housing triple-net facilities under direct financing leases recognized as a result of entering into sales agreements. For the year ended December 31, 2018, represents the impairment of an undeveloped life science land parcel classified as held for sale, partially offset by an impairment recovery upon the sale of a mezzanine loan investment in March 2018.
(4)
For the year ended December 31, 2018, primarily relates to the departure of our former Executive Chairman and corporate restructuring activities.
(5)
For all periods presented, represents the premium associated with the prepayment of senior unsecured notes.
(6)
For the three months ended December 31, 2019, represents evacuation costs related to hurricanes. The year ended December 31, 2019 also includes incremental insurance proceeds related to hurricanes in 2017.
(7)
Excludes amounts related to the acceleration of deferred compensation for restricted stock units that vested upon the departure of certain former employees, which have already been excluded from FFO as Adjusted in severance and related charges.
(8)
Represents our 49% share of our CCRC JV's non-refundable entrance fees collected in excess of amortization.
(9)
Primarily includes our share of FAD capital expenditures from unconsolidated joint ventures, partially offset by noncontrolling interests' share of FAD capital expenditures from consolidated joint ventures.




healthpeaklogohorizblkrgba01.jpg
7

Reconciliations
In thousands


Share of Unconsolidated Joint Venture NAREIT FFO, and FAD

 
 
Three Months Ended December 31, 2019
 
 
Total
 
CCRC JV
 
Other SHOP JVs
 
Senior Housing JV
 
U.K. JV
 
Medical Office
 
Remaining
Equity income (loss) from unconsolidated joint ventures
 
$
1,387

 
$
(2,456
)
 
$
(462
)
 
$
930

 
$
871

 
$
215

 
$
2,289

Real estate related depreciation and amortization
 
15,151

 
12,073

 
947

 
150

 
1,733

 
200

 
48

Loss (gain) on sales of real estate, net
 
(2,118
)
 

 

 

 

 

 
(2,118
)
NAREIT FFO
 
$
14,420

 
$
9,617

 
$
485

 
$
1,080

 
$
2,604

 
$
415

 
$
219

FAD adjustments
 
485

 
939

 
(116
)
 
(34
)
 
(288
)
 
(25
)
 
9

FAD
 
$
14,905

 
$
10,556

 
$
369

 
$
1,046

 
$
2,316

 
$
390

 
$
228





healthpeaklogohorizblkrgba01.jpg
8

Reconciliations
In thousands, except for per share data

Projected Future Operations(1)
 
Full Year 2020
 
Low
 
High
Diluted earnings per common share
$
0.70

 
$
0.76

Real estate related depreciation and amortization
1.40

 
1.40

Real estate related depreciation and amortization on unconsolidated joint ventures
0.20

 
0.20

Real estate related depreciation and amortization on noncontrolling interests and other
(0.03
)
 
(0.03
)
Loss (gain) on sales of real estate, net
(0.40
)
 
(0.40
)
Loss (gain) upon consolidation of real estate, net
(0.24
)
 
(0.24
)
Taxes associated with real estate disposition
0.01

 
0.01

Diluted NAREIT FFO per common share
$
1.64

 
$
1.70

Transaction-related items
0.21

 
0.21

Other impairments (recoveries), net
(0.08
)
 
(0.08
)
Diluted FFO as Adjusted per common share
$
1.77

 
$
1.83

 ______________________________________
(1)
The foregoing projections reflect management’s view of current and future market conditions as of February 11, 2020 including assumptions with respect to rental rates, occupancy levels, development items, and the earnings impact of the events referenced in our earnings press release for the quarter ended December 31, 2019 that was issued on February 11, 2020. However, these projections do not reflect the impact of unannounced future transactions, except as described herein, other impairments or recoveries, the future bankruptcy or insolvency of our operators, lessees, borrowers or other obligors, the effect of any future restructuring of our contractual relationships with such entities, gains or losses on marketable securities, ineffectiveness related to our cash flow hedges, or larger than expected litigation settlements and expenses related to existing or future litigation matters. Our actual results may differ materially from the projections set forth above. The aforementioned ranges represent management’s best estimates based upon the underlying assumptions as of February 11, 2020. Except as otherwise required by law, management assumes no, and hereby disclaims any, obligation to update any of the foregoing projections as a result of new information or new or future developments.

Share of Unconsolidated Joint Venture NAREIT FFO and Cash NOI
 
 
Full Year 2020
 
 
Low
 
High
Equity income (loss) from unconsolidated joint ventures
 
$
(72,000
)
 
$
(68,000
)
Real estate related depreciation and amortization
 
103,000

 
107,000

NAREIT FFO
 
$
31,000

 
$
39,000

Adjustments to NAREIT FFO(1)
 
3,500

 
3,500

Total NOI
 
$
34,500

 
$
42,500

Non-cash adjustments to NOI
 
(500
)
 
(500
)
Total Cash NOI
 
$
34,000

 
$
42,000

 ______________________________________
(1)
Includes interest and general and administrative expenses.



healthpeaklogohorizblkrgba01.jpg
9

Reconciliations
In millions


Projected SPP Cash NOI(1)(2)
For the projected full year 2020 (low)
 
Senior Housing(3)
 
Life Science
 
Medical Office
 
Other
 
Total
Cash NOI(4)
$
399

 
$
389

 
$
344

 
$
44

 
$
1,177

Interest income

 

 

 
15

 
15

Cash NOI plus interest income
399

 
389

 
344

 
59

 
1,191

Interest income

 

 

 
(15
)
 
(15
)
Non-cash adjustments to cash NOI(5)
2

 
27

 
7

 
(2
)
 
33

NOI
400

 
416

 
351

 
42

 
1,210

Non-SPP NOI
(242
)
 
(155
)
 
(43
)
 
(1
)
 
(441
)
SPP NOI
158

 
261

 
309

 
41

 
769

Non-cash adjustments to SPP NOI(5)
(2
)
 
(7
)
 
(7
)
 
2

 
(13
)
SPP cash NOI
$
156

 
$
254

 
$
302

 
$
43

 
755

Addback adjustments(6)
 
 
 
 
 
 
 
 
455

Other income and expenses(7)
 
 
 
 
 
 
 
 
357

Costs and expenses(8)
 
 
 
 
 
 
 
 
(1,182
)
Other impairments (recoveries), net
 
 
 
 
 
 
 
 

Net income (loss)
 
 
 
 
 
 
 
 
$
385


For the projected full year 2020 (high)
 
Senior Housing(3)
 
Life Science
 
Medical Office
 
Other
 
Total
Cash NOI(4)
$
411

 
$
392

 
$
348

 
$
45

 
$
1,195

Interest income

 

 

 
15

 
15

Cash NOI plus interest income
411

 
392

 
348

 
59

 
1,210

Interest income

 

 

 
(15
)
 
(15
)
Non-cash adjustments to cash NOI(5)
1

 
27

 
7

 
(2
)
 
33

NOI
412

 
419

 
355

 
42

 
1,228

Non-SPP NOI
(251
)
 
(156
)
 
(43
)
 
(1
)
 
(452
)
SPP NOI
161

 
263

 
312

 
41

 
776

Non-cash adjustments to SPP NOI(5)
(2
)
 
(7
)
 
(7
)
 
2

 
(13
)
SPP cash NOI
$
159

 
$
256

 
$
305

 
$
43

 
763

Addback adjustments(6)
 
 
 
 
 
 
 
 
465

Other income and expenses(7)
 
 
 
 
 
 
 
 
362

Costs and expenses(8)
 
 
 
 
 
 
 
 
(1,177
)
Other impairments (recoveries), net
 
 
 
 
 
 
 
 

Net income (loss)
 
 
 
 
 
 
 
 
$
412








healthpeaklogohorizblkrgba01.jpg
10

Reconciliations
In millions


For the year ended December 31, 2019
 
Senior Housing(3)
 
Life Science
 
Medical Office
 
Other
 
Total
Cash NOI(4)
$
423

 
$
311

 
$
342

 
$
53

 
$
1,129

Interest income


 


 


 
10

 
10

Cash NOI plus interest income
423

 
311

 
342

 
63

 
1,139

Interest income


 


 


 
(10
)
 
(10
)
Non-cash adjustments to cash NOI(5)
(23
)
 
22

 
6

 
(1
)
 
4

NOI
400

 
333

 
348

 
51

 
1,133

Non-SPP NOI
(241
)
 
(83
)
 
(44
)
 
(11
)
 
(379
)
SPP NOI
159

 
250

 
304

 
41

 
754

Non-cash adjustments to SPP NOI(5)
(2
)
 
(6
)
 
(7
)
 
1

 
(13
)
SPP cash NOI
$
157

 
$
244

 
$
297

 
$
42

 
741

Addback adjustments(6)
 
 
 
 
 
 
 
 
392

Other income and expenses(7)
 
 
 
 
 
 
 
 
199

Costs and expenses(8)
 
 
 
 
 
 
 
 
(1,046
)
Other impairments (recoveries), net
 
 
 
 
 
 
 
 
(226
)
Net income (loss)
 
 
 
 
 
 
 
 
$
60


Projected SPP Cash NOI change for the full year 2020
 
Senior Housing(3)
 
Life Science
 
Medical Office
 
Other
 
Total
Low
(1.00%)
 
4.00%
 
1.75%
 
1.75%
 
2.00%
High
1.00%
 
5.00%
 
2.75%
 
2.50%
 
3.00%
______________
(1)
The foregoing projections reflect management’s view of current and future market conditions as of February 11, 2020 including assumptions with respect to rental rates, occupancy levels, development items, and the earnings impact of the events referenced in our earnings press release for the quarter ended December 31, 2019 that was issued on February 11, 2020. However, these projections do not reflect the impact of unannounced future transactions, except as described herein, other impairments or recoveries, the future bankruptcy or insolvency of our operators, lessees, borrowers or other obligors, the effect of any future restructuring of our contractual relationships with such entities, gains or losses on marketable securities, ineffectiveness related to our cash flow hedges, or larger than expected litigation settlements and expenses related to existing or future litigation matters. Our actual results may differ materially from the projections set forth above. The aforementioned ranges represent management’s best estimates based upon the underlying assumptions as of February 11, 2020. Except as otherwise required by law, management assumes no, and hereby disclaims any, obligation to update any of the foregoing projections as a result of new information or new or future developments.
(2)
Does not foot due to rounding and adjustments made to SPP high and low ranges reported by segment.
(3)
Includes senior housing triple-net and SHOP.
(4)
Represents rental and related revenues, tenant recoveries, resident fees and services, and income from DFLs, less property level operating expenses, including our share of our joint ventures.
(5)
Represents straight-line rents, DFL non-cash interest, amortization of market lease intangibles, net, the deferral of community fees, net of amortization, management contract termination expense, actuarial reserves for insurance claims that have been incurred but not reported, and lease termination fees.
(6)
Represents non-SPP NOI and non-cash adjustments to SPP NOI.
(7)
Represents interest income, gain (loss) on sales of real estate, net, other income (expense), net, income taxes benefit (expense), and equity income (loss) from unconsolidated joint ventures, excluding NOI.
(8)
Represents interest expense, depreciation and amortization, general and administrative, transaction costs, and loss on debt extinguishments.



healthpeaklogohorizblkrgba01.jpg
11

Reconciliations
In thousands


Enterprise Gross Assets and Portfolio Investment
 
December 31, 2019
 
Senior Housing Triple-net
 
SHOP
 
Life Science
 
Medical Office
 
Other
 
Corporate Non-segment
 
Total
Consolidated total assets
$
1,081,486

 
$
2,841,730

 
$
5,117,051

 
$
3,615,493

 
$
1,248,701

 
$
128,430

 
$
14,032,891

Investments in and advances to unconsolidated JVs

 

 

 

 
(825,515
)
 

 
(825,515
)
Accumulated depreciation and amortization
438,593

 
632,206

 
822,393

 
1,329,661

 
96,544

 

 
3,319,397

Consolidated Gross Assets
$
1,520,079

 
$
3,473,936

 
$
5,939,444

 
$
4,945,154

 
$
519,730

 
$
128,430

 
$
16,526,773

Share of unconsolidated JV gross assets

 

 

 

 
1,617,062

 

 
1,617,062

Enterprise Gross Assets
$
1,520,079

 
$
3,473,936

 
$
5,939,444

 
$
4,945,154

 
$
2,136,792

 
$
128,430

 
$
18,143,835

Land held for development

 

 
(96,882
)
 
(9,458
)
 

 

 
(106,340
)
Fully depreciated real estate and intangibles
54,646

 
94,619

 
339,814

 
439,634

 
9,181

 

 
937,894

Non-real estate related assets(1)
(118,947
)
 
(202,861
)
 
(230,086
)
 
(298,525
)
 
(277,556
)
 
(128,430
)
 
(1,256,405
)
Real estate intangible liabilities
(18,709
)
 
(8,599
)
 
(96,494
)
 
(89,952
)
 
(4,871
)
 

 
(218,625
)
Portfolio Investment
$
1,437,069

 
$
3,357,095

 
$
5,855,796

 
$
4,986,853

 
$
1,863,546

 
$

 
$
17,500,359

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Investment by Type:
 
 
 
 
 
 
 
 
 
 
 
 
 
Wholly-owned
$
1,437,069

 
$
3,357,095

 
$
5,855,796

 
$
4,986,853

 
$
504,794

 
$

 
$
16,141,607

Share of unconsolidated JVs

 

 

 

 
1,358,752

 

 
1,358,752

Portfolio Investment
$
1,437,069

 
$
3,357,095

 
$
5,855,796

 
$
4,986,853

 
$
1,863,546

 
$

 
$
17,500,359

______________________________________
(1)
Includes straight-line rent payables and receivables, net of reserves; lease commissions - 2nd generation, net of amortization; cash and restricted cash; our share of the value attributable to refundable Entrance Fee liabilities for the CCRC JV; operating lease right-of-use assets; and other assets.

 





healthpeaklogohorizblkrgba01.jpg
12

Reconciliations
In thousands


Real Estate Revenue
 
Three Months Ended
 
December 31, 2018
 
March 31, 2019
 
June 30, 2019
 
September 30, 2019
 
December 31, 2019
Senior housing triple-net
$
63,602

 
$
58,892

 
$
49,866

 
$
48,018

 
$
42,665

SHOP
127,909

 
126,181

 
177,001

 
212,275

 
209,714

Life science
96,371

 
94,473

 
107,596

 
118,561

 
120,155

Medical office(1)
140,015

 
142,195

 
141,927

 
143,639

 
143,769

Other(1)
12,664

 
12,700

 
12,763

 
12,737

 
12,412

Real Estate Revenue
$
440,561

 
$
434,441

 
$
489,153

 
$
535,230

 
$
528,715

Senior housing triple-net
2,436

 
435

 
4,793

 
(1,551
)
 
(2,201
)
SHOP
41

 
968

 
1,128

 
957

 
258

Life science
(2,178
)
 
(2,491
)
 
(7,627
)
 
(7,080
)
 
(4,975
)
Medical office(1)
(2,506
)
 
(2,710
)
 
(2,143
)
 
(2,509
)
 
(2,267
)
Other(1)
194

 
194

 
219

 
469

 
461

Non-cash adjustments to Real Estate Revenues
$
(2,013
)
 
$
(3,604
)
 
$
(3,630
)
 
$
(9,714
)
 
$
(8,724
)
Senior housing triple-net
66,038

 
59,328

 
54,659

 
46,467

 
40,464

SHOP
127,950

 
127,149

 
178,129

 
213,232

 
209,972

Life science
94,193

 
91,982

 
99,969

 
111,481

 
115,180

Medical office(1)
137,509

 
139,485

 
139,784

 
141,130

 
141,502

Other(1)
12,858

 
12,895

 
12,982

 
13,206

 
12,873

Cash Real Estate Revenues
$
438,548

 
$
430,839

 
$
485,523

 
$
525,516

 
$
519,991

Senior housing triple-net
(44,042
)
 
(37,331
)
 
(32,369
)
 
(24,165
)
 
(18,023
)
SHOP
(87,800
)
 
(85,719
)
 
(136,605
)
 
(171,454
)
 
(168,715
)
Life science
(16,455
)
 
(14,277
)
 
(20,255
)
 
(29,650
)
 
(33,038
)
Medical office(1)
(10,529
)
 
(10,133
)
 
(10,040
)
 
(9,683
)
 
(9,732
)
Other(1)
(484
)
 
(463
)
 
(479
)
 
(477
)
 
(92
)
Non-SPP Cash Real Estate Revenues
$
(159,310
)
 
$
(147,923
)
 
$
(199,748
)
 
$
(235,429
)
 
$
(229,600
)
Senior housing triple-net
21,996

 
21,997

 
22,290

 
22,302

 
22,441

SHOP
40,150

 
41,430

 
41,524

 
41,778

 
41,257

Life science
77,738

 
77,705

 
79,714

 
81,831

 
82,142

Medical office(1)
126,980

 
129,352

 
129,744

 
131,447

 
131,770

Other(1)
12,374

 
12,432

 
12,503

 
12,729

 
12,781

Cash Real Estate Revenues - SPP
$
279,238

 
$
282,916

 
$
285,775

 
$
290,087

 
$
290,391

_______________________________________
(1)
During the quarter ended March 31, 2019, two facilities were reclassified from the other non-reportable segments to the medical office segment. Accordingly, all prior period segment information has been recast to conform to the current period presentation.





healthpeaklogohorizblkrgba01.jpg
13

Reconciliations
In thousands


Operating Expenses
 
Three Months Ended
 
December 31, 2018
 
March 31, 2019
 
June 30, 2019
 
September 30, 2019
 
December 31, 2019
Senior housing triple-net
$
941

 
$
993

 
$
866

 
$
865

 
$
1,842

SHOP
104,617

 
96,948

 
137,460

 
166,201

 
165,104

Life science
23,534

 
21,992

 
25,480

 
29,520

 
30,480

Medical office(1)
48,219

 
48,987

 
50,176

 
51,472

 
50,903

Other(1)
102

 
7

 
11

 
11

 
53

Operating expenses
$
177,413

 
$
168,927

 
$
213,993

 
$
248,069

 
$
248,382

Senior housing triple-net
(14
)
 
(129
)
 
(14
)
 
(14
)
 
(1,093
)
SHOP
(3,189
)
 
(184
)
 
287

 
218

 
119

Life science
(13
)
 
(13
)
 
(13
)
 
(13
)
 
(13
)
Medical office(1)
(945
)
 
(939
)
 
(940
)
 
(941
)
 
(932
)
Other(1)

 
1

 

 

 
1

Non-cash adjustments to operating expenses
$
(4,161
)
 
$
(1,264
)
 
$
(680
)
 
$
(750
)
 
$
(1,918
)
Senior housing triple-net
927

 
864

 
852

 
851

 
749

SHOP
101,428

 
96,764

 
137,747

 
166,419

 
165,223

Life science
23,521

 
21,979

 
25,467

 
29,507

 
30,467

Medical office(1)
47,274

 
48,048

 
49,236

 
50,531

 
49,971

Other(1)
102

 
8

 
11

 
11

 
54

Cash Operating Expenses
$
173,252

 
$
167,663

 
$
213,313

 
$
247,319

 
$
246,464

Senior housing triple-net
(892
)
 
(834
)
 
(822
)
 
(820
)
 
(725
)
SHOP
(71,273
)
 
(66,516
)
 
(107,202
)
 
(135,608
)
 
(134,556
)
Life science
(4,763
)
 
(4,453
)
 
(6,252
)
 
(9,648
)
 
(10,436
)
Medical office(1)
(4,456
)
 
(4,518
)
 
(4,841
)
 
(4,783
)
 
(4,669
)
Other(1)
(93
)
 
(3
)
 
(6
)
 
(6
)
 
26

Non-SPP operating expenses
$
(81,477
)
 
$
(76,324
)
 
$
(119,123
)
 
$
(150,865
)
 
$
(150,360
)
Senior housing triple-net
35

 
30

 
30

 
31

 
24

SHOP
30,155

 
30,248

 
30,545

 
30,811

 
30,667

Life science
18,758

 
17,526

 
19,215

 
19,859

 
20,031

Medical office(1)
42,818

 
43,530

 
44,395

 
45,748

 
45,302

Other(1)
9

 
5

 
5

 
5

 
80

Cash Operating Expenses - SPP
$
91,775

 
$
91,339

 
$
94,190

 
$
96,454

 
$
96,104

_______________________________________
(1)
During the quarter ended March 31, 2019, two facilities were reclassified from the other non-reportable segments to the medical office segment. Accordingly, all prior period segment information has been recast to conform to the current period presentation.






healthpeaklogohorizblkrgba01.jpg
14

Reconciliations
In thousands


Total Real Estate Revenue
 
Total Operating Expenses
Year Ended
December 31, 2019
 
Year Ended
December 31, 2019
Senior housing triple-net
$
199,441

 
Senior housing triple-net
$
4,565

SHOP
725,171

 
SHOP
565,713

Life science
440,784

 
Life science
107,472

Medical office
571,530

 
Medical office
201,538

Other
50,613

 
Other
82

Real Estate Revenue
$
1,987,539

 
Operating expenses
$
879,370

Senior housing triple-net
1,476

 
Senior housing triple-net
(1,249
)
SHOP
3,311

 
SHOP
439

Life science
(22,172
)
 
Life science
(52
)
Medical office
(9,628
)
 
Medical office
(3,751
)
Other
1,342

 
Other

Non-cash adjustments to Real Estate Revenues
$
(25,671
)
 
Non-cash adjustments to operating expenses
$
(4,613
)
Senior housing triple-net
200,917

 
Senior housing triple-net
3,316

SHOP
728,482

 
SHOP
566,152

Life science
418,612

 
Life science
107,420

Medical office
561,902

 
Medical office
197,787

Other
51,955

 
Other
82

Cash Real Estate Revenues
$
1,961,868

 
Cash Operating Expenses
$
874,757

Senior housing triple-net
(111,887
)
 
Senior housing triple-net
(3,202
)
SHOP
(608,486
)
 
SHOP
(478,515
)
Life science
(127,212
)
 
Life science
(38,050
)
Medical office
(90,582
)
 
Medical office
(37,308
)
Other
(1,509
)
 
Other
13

Non-SPP Cash Real Estate Revenues(1)
$
(939,676
)
 
Non-SPP operating expenses(2)
$
(557,062
)
Senior housing triple-net
89,030

 
Senior housing triple-net
114

SHOP
119,996

 
SHOP
87,637

Life science
291,400

 
Life science
69,370

Medical office
471,320

 
Medical office
160,479

Other
50,446

 
Other
95

Cash Real Estate Revenues - SPP(1)
$
1,022,192

 
Cash Operating Expenses - SPP(2)
$
317,695

___________________________________
(1)
The property count used for Non-SPP Cash Real Estate Revenues and Cash Real Estate Revenues - SPP differed for the three and twelve months ended December 31, 2019.
(2)
The property count used for Non-SPP operating expense and Cash Operating Expenses - SPP differed for the three and twelve months ended December 31, 2019.










healthpeaklogohorizblkrgba01.jpg
15

Reconciliations
In thousands


Total Real Estate Revenue
 
Total Operating Expenses
Year Ended
December 31, 2018
 
Year Ended
December 31, 2018
Senior housing triple-net
$
276,091

 
Senior housing triple-net
$
3,618

SHOP
547,976

 
SHOP
414,312

Life science
395,064

 
Life science
91,742

Medical office(1)
547,375

 
Medical office(1)
195,100

Other(1)
69,777

 
Other(1)
266

Real Estate Revenue
$
1,836,283

 
Operating expenses
$
705,038

Senior housing triple-net
2,120

 
Senior housing triple-net
(7
)
SHOP
(3,193
)
 
SHOP
(6,068
)
Life science
(9,652
)
 
Life science
(63
)
Medical office(1)
(10,077
)
 
Medical office(1)
(3,387
)
Other(1)
(627
)
 
Other(1)

Non-cash adjustments to Real Estate Revenues
$
(21,429
)
 
Non-cash adjustments to operating expenses
$
(9,525
)
Senior housing triple-net
278,211

 
Senior housing triple-net
3,611

SHOP
544,783

 
SHOP
408,244

Life science
385,412

 
Life science
91,679

Medical office(1)
537,298

 
Medical office(1)
191,713

Other(1)
69,150

 
Other(1)
266

Cash Real Estate Revenues
$
1,814,854

 
Cash Operating Expenses
$
695,513

Senior housing triple-net
(191,287
)
 
Senior housing triple-net
(3,486
)
SHOP
(427,973
)
 
SHOP
(324,121
)
Life science
(111,314
)
 
Life science
(26,725
)
Medical office(1)
(78,227
)
 
Medical office(1)
(34,383
)
Other(1)
(20,069
)
 
Other(1)
(242
)
Non-SPP Cash Real Estate Revenues(2)
$
(828,870
)
 
Non-SPP operating expenses(3)
$
(388,957
)
Senior housing triple-net
86,924

 
Senior housing triple-net
125

SHOP
116,810

 
SHOP
84,123

Life science
274,098

 
Life science
64,954

Medical office(1)
459,071

 
Medical office(1)
157,330

Other(1)
49,081

 
Other(1)
24

Cash Real Estate Revenues - SPP(2)
$
985,984

 
Cash Operating Expenses - SPP(3)
$
306,556

___________________________________
(1)
During the year ended December 31, 2019, two facilities were reclassified from the other non-reportable segments to the medical office segment. Accordingly, all prior year segment information has been recast to conform to the current year presentation.
(2)
The property count used for Non-SPP Cash Real Estate Revenues and Cash Real Estate Revenues - SPP differed for the three and twelve months ended December 31, 2018.
(3)
The property count used for Non-SPP operating expense and Cash Operating Expenses - SPP differed for the three and twelve months ended December 31, 2018.



healthpeaklogohorizblkrgba01.jpg
16

Reconciliations
In thousands


EBITDAre and Adjusted EBITDAre
 
Three Months Ended
December 31, 2019
 
Twelve Months Ended
December 31, 2019
Net income (loss)
$
47,359


$
60,061

Interest expense
58,120


225,619

Income tax expense (benefit)
(5,679
)

(17,262
)
Depreciation and amortization
190,798


659,989

Other depreciation and amortization
2,166

 
9,158

Loss (gain) on sales of real estate
(4,193
)
 
(22,900
)
Loss (gain) upon change of control
(155,225
)
 
(168,023
)
Impairments (recoveries) of depreciable real estate
110,284

 
215,790

Share of unconsolidated JV:
 
 
 
  Interest expense
3,289

 
14,825

  Income tax expense (benefit)
183

 
674

  Depreciation and amortization
15,151


60,303

  Impairments (recoveries) of depreciable real estate


5,527

  Gain on sale of real estate from unconsolidated JVs
(2,118
)
 
(2,118
)
  Other JV adjustments
(400
)

(2,010
)
EBITDAre
$
259,735


$
1,039,633

 
 



Transaction-related items
1,688

 
15,347

Other impairments (recoveries) and losses (gains)


10,147

Severance and related charges


5,063

Loss on debt extinguishments
22,213


58,364

Litigation costs (recoveries)
29


(520
)
Casualty-related charges (recoveries)
700


(3,706
)
Amortization of deferred compensation
3,177

 
14,790

Foreign currency remeasurement losses (gains)
100

 
(250
)
CCRC entrance fees(1)
4,785


18,856

Adjusted EBITDAre
$
292,427


$
1,157,724




Adjusted Fixed Charge Coverage
 
Three Months Ended
December 31, 2019
 
Twelve Months Ended
December 31, 2019
Interest expense
$
58,120

 
$
225,619

Capitalized interest
7,630

 
30,109

Share of unconsolidated JV interest expense and capitalized interest
3,555

 
15,686

Fixed Charges
$
69,305

 
$
271,414

 
 
 
 
Adjusted Fixed Charge Coverage
  4.2x

 
  4.3x

  ______________________________________
(1)
Represents our 49% share of our CCRC JV's non-refundable entrance fees collected in excess of amortization.

healthpeaklogohorizblkrgba01.jpg
17

Reconciliations
In thousands


Enterprise Debt and Net Debt
 
December 31, 2019
Bank line of credit and commercial paper(1)
$
93,000

Term loan
248,942

Senior unsecured notes
5,647,993

Mortgage debt(2)
309,196

Other debt
84,771

Consolidated Debt
$
6,383,902

Share of unconsolidated JV mortgage debt
184,218

Share of unconsolidated JV other debt
164,543

Enterprise Debt
$
6,732,663

Cash and cash equivalents
(144,232
)
Share of unconsolidated JV cash and cash equivalents
(31,520
)
Net Debt
$
6,556,911

Financial Leverage
 
December 31, 2019
Enterprise Debt
$
6,732,663

Enterprise Gross Assets
18,143,835

Financial Leverage
37.1%

Secured Debt Ratio
 
December 31, 2019
Mortgage debt
$
309,196

Share of unconsolidated JV mortgage debt
184,218

Enterprise Secured Debt
$
493,414

Enterprise Gross Assets
18,143,835

Secured Debt Ratio
2.7%

Net Debt to Adjusted EBITDAre
 
Three Months Ended
December 31, 2019
Twelve Months Ended December 31, 2019
Net Debt
$
6,556,911

 
$
6,556,911

Adjusted EBITDAre
1,169,708

(3) 
1,157,724

Net Debt to Adjusted EBITDAre
  5.6x

 
  5.7x

  ______________________________________
(1)
Includes $93 million of commercial paper at December 31, 2019.
(2)
Includes mortgage debt of $32.3 million on assets held for sale that matures in 2026, 2028 and 2044.
(3)
Represents the current quarter Adjusted EBIDTAre multiplied by a factor of four.



healthpeaklogohorizblkrgba01.jpg
18

Reconciliations
In thousands


Segment Cash NOI, Portfolio Income, and SPP
Total Consolidated
 
Three Months Ended
 
December 31, 2018
 
March 31, 2019
 
June 30, 2019
 
September 30, 2019
 
December 31, 2019
Net income (loss)
$
834,383

 
$
64,990

 
$
(9,980
)
 
$
(42,308
)
 
$
47,359

Interest income
(1,358
)
 
(1,713
)
 
(2,414
)
 
(2,741
)
 
(2,976
)
Interest expense
54,717

 
49,327

 
56,942

 
61,230

 
58,120

Depreciation and amortization
130,759

 
131,951

 
165,296

 
171,944

 
190,798

General and administrative
21,510

 
21,355

 
27,120

 
22,970

 
21,521

Transaction costs
1,684

 
4,518

 
1,337

 
1,319

 
1,569

Loss (gain) on sales of real estate, net
(763,774
)
 
(8,044
)
 
(11,448
)
 
784

 
(4,193
)
Impairments (recoveries), net
36,080

 
8,858

 
68,538

 
38,257

 
110,284

Other expense (income), net
(50,333
)
 
(3,133
)
 
(21,008
)
 
(693
)
 
(157,296
)
Loss on debt extinguishments
263

 

 
1,135

 
35,017

 
22,213

Income tax expense (benefit)
(2,935
)
 
(3,458
)
 
(1,864
)
 
(6,261
)
 
(5,679
)
Equity loss (income) from unconsolidated JVs
2,152

 
863

 
1,506

 
7,643

 
(1,387
)
NOI
$
263,148

 
$
265,514

 
$
275,160

 
$
287,161

 
$
280,333

Adjustment to NOI
2,148

 
(2,338
)
 
(2,950
)
 
(8,963
)
 
(6,805
)
Cash NOI
$
265,296

 
$
263,176

 
$
272,210

 
$
278,198

 
$
273,528

Interest income
1,358

 
1,713

 
2,414

 
2,741

 
2,976

Share of unconsolidated JVs
21,466

 
21,400

 
22,233

 
21,569

 
20,765

Portfolio Income
$
288,120

 
$
286,289

 
$
296,857

 
$
302,508

 
$
297,269

Interest income
(1,358
)
 
(1,713
)
 
(2,414
)
 
(2,741
)
 
(2,976
)
Share of unconsolidated JVs
(21,466
)
 
(21,400
)
 
(22,233
)
 
(21,569
)
 
(20,765
)
Adjustment to NOI
(2,148
)
 
2,338

 
2,950

 
8,963

 
6,805

Non-SPP NOI
(74,992
)
 
(72,080
)
 
(81,581
)
 
(90,012
)
 
(84,387
)
SPP NOI
$
188,156

 
$
193,434

 
$
193,579

 
$
197,149

 
$
195,946

Non-cash adjustment to SPP NOI
(693
)
 
(1,857
)
 
(1,994
)
 
(3,516
)
 
(1,659
)
SPP cash NOI
$
187,463

 
$
191,577

 
$
191,585

 
$
193,633

 
$
194,287




healthpeaklogohorizblkrgba01.jpg
19

Reconciliations
In thousands


Senior Housing Triple-Net
 
Three Months Ended
 
December 31, 2018
 
March 31, 2019
 
June 30, 2019
 
September 30, 2019
 
December 31, 2019
Net income (loss)
$
67,827

 
$
44,184

 
$
17,616

 
$
26,839

 
$
9,570

Interest expense
598

 
589

 
206

 
106

 
102

Depreciation and amortization
17,564

 
16,683

 
15,693

 
12,778

 
10,207

Impairments (recoveries), net

 

 
15,485

 
7,430

 
20,944

Loss (gain) on sales of real estate, net
(23,328
)
 
(3,557
)
 

 

 

NOI
$
62,661

 
$
57,899

 
$
49,000

 
$
47,153

 
$
40,823

Adjustment to NOI
2,450

 
564

 
4,807

 
(1,537
)
 
(1,108
)
Cash NOI
$
65,111

 
$
58,463

 
$
53,807

 
$
45,616

 
$
39,715

Interest income

 

 

 

 

Share of unconsolidated JVs

 

 

 

 

Portfolio Income
$
65,111

 
$
58,463

 
$
53,807

 
$
45,616

 
$
39,715

Interest income

 

 

 

 

Share of unconsolidated JVs

 

 

 

 

Adjustment to NOI
(2,450
)
 
(564
)
 
(4,807
)
 
1,537

 
1,108

Non-SPP NOI
(41,169
)
 
(36,599
)
 
(27,212
)
 
(23,689
)
 
(17,333
)
SPP NOI
$
21,492

 
$
21,300

 
$
21,788

 
$
23,464

 
$
23,490

Non-cash adjustment to SPP NOI
469

 
667

 
472

 
(1,193
)
 
(1,073
)
SPP cash NOI
$
21,961

 
$
21,967

 
$
22,260

 
$
22,271

 
$
22,417


SHOP
 
Three Months Ended
 
December 31, 2018
 
March 31, 2019
 
June 30, 2019
 
September 30, 2019
 
December 31, 2019
Net income (loss)
$
(19,145
)
 
$
8,971

 
$
(62,299
)
 
$
(40,170
)
 
$
46,354

Interest expense
659

 
663

 
1,326

 
2,637

 
2,893

Depreciation and amortization
23,609

 
24,086

 
52,242

 
58,152

 
80,106

Impairments (recoveries), net
32,802

 

 
52,963

 
24,721

 
86,684

Loss (gain) on sales of real estate, net
(14,633
)
 
(4,487
)
 
(4,691
)
 
734

 
(10,541
)
Other expense (income), net

 

 

 

 
(160,886
)
NOI
$
23,292

 
$
29,233

 
$
39,541

 
$
46,074

 
$
44,610

Adjustment to NOI
3,230

 
1,152

 
841

 
740

 
139

Cash NOI
$
26,522

 
$
30,385

 
$
40,382

 
$
46,814

 
$
44,749

Interest income

 

 

 

 

Share of unconsolidated JVs

 

 

 

 

Portfolio Income
$
26,522

 
$
30,385

 
$
40,382

 
$
46,814

 
$
44,749

Interest income

 

 

 

 

Share of unconsolidated JVs

 

 

 

 

Adjustment to NOI
(3,230
)
 
(1,152
)
 
(841
)
 
(740
)
 
(139
)
Non-SPP NOI
(14,887
)
 
(18,291
)
 
(28,720
)
 
(35,172
)
 
(34,014
)
SPP NOI
$
8,405

 
$
10,942

 
$
10,821

 
$
10,902

 
$
10,596

Non-cash adjustment to SPP NOI
1,590

 
240

 
158

 
65

 
(6
)
SPP cash NOI
$
9,995

 
$
11,182

 
$
10,979

 
$
10,967

 
$
10,590


healthpeaklogohorizblkrgba01.jpg
20

Reconciliations
In thousands


Life Science
 
Three Months Ended
 
December 31, 2018
 
March 31, 2019
 
June 30, 2019
 
September 30, 2019
 
December 31, 2019
Net income (loss)
$
763,666

 
$
36,162

 
$
44,431

 
$
43,858

 
$
43,975

Interest expense
76

 
73

 
70

 
68

 
66

Depreciation and amortization
34,699

 
36,246

 
41,431

 
45,028

 
45,634

Impairments (recoveries), net

 

 

 

 

Loss (gain) on sales of real estate, net
(725,604
)
 

 
(3,816
)
 
87

 

NOI
$
72,837

 
$
72,481

 
$
82,116

 
$
89,041

 
$
89,675

Adjustment to NOI
(2,165
)
 
(2,478
)
 
(7,614
)
 
(7,067
)
 
(4,961
)
Cash NOI
$
70,672

 
$
70,003

 
$
74,502

 
$
81,974

 
$
84,714

Interest income

 

 

 

 

Share of unconsolidated JVs

 

 

 

 

Portfolio Income
$
70,672

 
$
70,003

 
$
74,502

 
$
81,974

 
$
84,714

Interest income

 

 

 

 

Share of unconsolidated JVs

 

 

 

 

Adjustment to NOI
2,165

 
2,478

 
7,614

 
7,067

 
4,961

Non-SPP NOI
(12,496
)
 
(11,146
)
 
(19,969
)
 
(25,698
)
 
(27,746
)
SPP NOI
$
60,341

 
$
61,335

 
$
62,147

 
$
63,343

 
$
61,929

Non-cash adjustment to SPP NOI
(1,361
)
 
(1,156
)
 
(1,648
)
 
(1,371
)
 
182

SPP cash NOI
$
58,980

 
$
60,179

 
$
60,499

 
$
61,972

 
$
62,111


Medical Office(1) 
 
Three Months Ended
 
December 31, 2018
 
March 31, 2019
 
June 30, 2019
 
September 30, 2019
 
December 31, 2019
Net income (loss)
$
39,042

 
$
31,138

 
$
40,397

 
$
32,171

 
$
37,045

Interest expense
118

 
111

 
109

 
108

 
105

Depreciation and amortization
53,163

 
53,101

 
54,096

 
54,152

 
53,323

Impairments (recoveries), net

 
8,858

 
90

 
5,729

 
2,656

Loss (gain) on sales of real estate, net
(527
)
 

 
(2,941
)
 
7

 
(263
)
NOI
$
91,796

 
$
93,208

 
$
91,751

 
$
92,167

 
$
92,866

Adjustment to NOI
(1,561
)
 
(1,771
)
 
(1,203
)
 
(1,568
)
 
(1,335
)
Cash NOI
$
90,235

 
$
91,437

 
$
90,548

 
$
90,599

 
$
91,531

Interest income

 

 

 

 

Share of unconsolidated JVs

 

 

 

 

Portfolio Income
$
90,235

 
$
91,437

 
$
90,548

 
$
90,599

 
$
91,531

Interest income

 

 

 

 

Share of unconsolidated JVs

 

 

 

 

Adjustment to NOI
1,561

 
1,771

 
1,203

 
1,568

 
1,335

Non-SPP NOI
(6,048
)
 
(5,584
)
 
(5,209
)
 
(4,982
)
 
(5,174
)
SPP NOI
$
85,748

 
$
87,624

 
$
86,542

 
$
87,185

 
$
87,692

Non-cash adjustment to SPP NOI
(1,586
)
 
(1,802
)
 
(1,193
)
 
(1,486
)
 
(1,224
)
SPP cash NOI
$
84,162

 
$
85,822

 
$
85,349

 
$
85,699

 
$
86,468



healthpeaklogohorizblkrgba01.jpg
21

Reconciliations
In thousands


Other(1) 
 
Three Months Ended
 
December 31, 2018
 
March 31, 2019
 
June 30, 2019
 
September 30, 2019
 
December 31, 2019
Net income (loss)
$
56,619

 
$
11,708

 
$
24,643

 
$
6,637

 
$
2,918

Interest income
(1,358
)
 
(1,713
)
 
(2,414
)
 
(2,741
)
 
(2,976
)
Interest expense

 

 

 

 

Depreciation and amortization
1,724

 
1,835

 
1,834

 
1,834

 
1,528

Impairments (recoveries), net
3,278

 

 

 
377

 

Loss (gain) on sales of real estate, net
318

 

 

 
(44
)
 
6,611

Other expense (income), net
(50,171
)
 

 
(12,817
)
 
(980
)
 
5,665

Equity loss (income) from unconsolidated JVs
2,152

 
863

 
1,506

 
7,643

 
(1,387
)
NOI
$
12,562

 
$
12,693

 
$
12,752

 
$
12,726

 
$
12,359

Adjustment to NOI
194

 
195

 
219

 
469

 
460

Cash NOI
$
12,756

 
$
12,888

 
$
12,971

 
$
13,195

 
$
12,819

Interest income
1,358

 
1,713

 
2,414

 
2,741

 
2,976

Share of unconsolidated JVs
21,466

 
21,400

 
22,233

 
21,569

 
20,765

Portfolio Income
$
35,580

 
$
36,001

 
$
37,618

 
$
37,505

 
$
36,560

Interest income
(1,358
)
 
(1,713
)
 
(2,414
)
 
(2,741
)
 
(2,976
)
Share of unconsolidated JVs
(21,466
)
 
(21,400
)
 
(22,233
)
 
(21,569
)
 
(20,765
)
Adjustment to NOI
(194
)
 
(195
)
 
(219
)
 
(469
)
 
(460
)
Non-SPP NOI
(392
)
 
(460
)
 
(471
)
 
(471
)
 
(120
)
SPP NOI
$
12,170

 
$
12,233

 
$
12,281

 
$
12,255

 
$
12,239

Non-cash adjustment to SPP NOI
195

 
194

 
217

 
469

 
462

SPP cash NOI
$
12,365

 
$
12,427

 
$
12,498

 
$
12,724

 
$
12,701


Corporate Non-Segment
 
Three Months Ended
 
December 31, 2018
 
March 31, 2019
 
June 30, 2019
 
September 30, 2019
 
December 31, 2019
Net income (loss)
$
(73,626
)
 
$
(67,173
)
 
$
(74,768
)
 
$
(111,643
)
 
$
(92,503
)
Interest expense
53,266

 
47,891

 
55,231

 
58,311

 
54,954

General and administrative
21,510

 
21,355

 
27,120

 
22,970

 
21,521

Transaction costs
1,684

 
4,518

 
1,337

 
1,319

 
1,569

Other expense (income), net
(162
)
 
(3,133
)
 
(8,191
)
 
287

 
(2,075
)
Loss on debt extinguishments
263

 

 
1,135

 
35,017

 
22,213

Income tax expense (benefit)
(2,935
)
 
(3,458
)
 
(1,864
)
 
(6,261
)
 
(5,679
)
NOI
$

 
$

 
$

 
$

 
$

  _______________________________________
(1)
During the quarter ended March 31, 2019, two facilities were reclassified from the other non-reportable segments to the medical office segment. Accordingly, all prior period segment information has been recast to conform to the current period presentation.





healthpeaklogohorizblkrgba01.jpg
22

Reconciliations
In thousands


Segment Cash NOI Same Property Performance
For the year ended December 31, 2019
 
 
Senior Housing Triple-Net
 
SHOP
 
Life Science
 
Medical Office(1)
 
Other(1)
 
Corporate Non-segment
 
Total
Net income (loss)
 
$
98,210

 
$
(46,750
)
 
$
168,347

 
$
140,696

 
$
45,649

 
$
(346,091
)
 
$
60,061

Interest income
 

 

 

 

 
(9,844
)
 

 
(9,844
)
Interest expense
 
1,003

 
7,519

 
277

 
434

 

 
216,386

 
225,619

Depreciation and amortization
 
55,361

 
214,590

 
168,339

 
214,669

 
7,030

 

 
659,989

General and administrative
 

 

 

 

 

 
92,966

 
92,966

Transaction costs
 

 

 

 

 

 
8,743

 
8,743

Loss (gain) on sales of real estate, net
 
(3,557
)
 
(19,384
)
 
(3,651
)
 
(3,139
)
 
6,831

 

 
(22,900
)
Impairments (recoveries), net
 
43,859

 
164,369

 

 
17,332

 
377

 

 
225,937

Other expense (income), net
 

 
(160,886
)
 

 

 
(8,137
)
 
(13,106
)
 
(182,129
)
Loss on debt extinguishments
 

 

 

 

 

 
58,364

 
58,364

Income tax expense (benefit)
 

 

 

 

 

 
(17,262
)
 
(17,262
)
Equity loss (income) from unconsolidated JVs
 

 

 

 

 
8,625

 

 
8,625

NOI
 
$
194,876

 
$
159,458

 
$
333,312

 
$
369,992

 
$
50,531

 
$

 
$
1,108,169

Adjustment to NOI
 
2,725

 
2,872

 
(22,120
)
 
(5,877
)
 
1,342

 

 
(21,058
)
Cash NOI
 
$
197,601

 
$
162,330

 
$
311,192

 
$
364,115

 
$
51,873

 
$

 
$
1,087,111

Interest income
 

 

 

 

 
9,844

 

 
9,844

Share of unconsolidated JVs
 

 

 

 

 
85,967

 

 
85,967

Portfolio Income
 
$
197,601

 
$
162,330

 
$
311,192

 
$
364,115

 
$
147,684

 
$

 
$
1,182,922

Interest income
 

 

 

 

 
(9,844
)
 

 
(9,844
)
Share of unconsolidated JVs
 

 

 

 

 
(85,967
)
 

 
(85,967
)
Adjustment to NOI
 
(2,725
)
 
(2,872
)
 
22,120

 
5,877

 
(1,342
)
 

 
21,058

Non-SPP NOI
 
(104,834
)
 
(127,221
)
 
(109,334
)
 
(54,708
)
 
(1,523
)
 

 
(397,620
)
SPP NOI
 
$
90,042

 
$
32,237

 
$
223,978

 
$
315,284

 
$
49,008

 
$

 
$
710,549

Non-cash adjustment to SPP NOI
 
(1,126
)
 
122

 
(1,948
)
 
(4,443
)
 
1,343

 

 
(6,052
)
SPP cash NOI
 
$
88,916

 
$
32,359

 
$
222,030

 
$
310,841

 
$
50,351

 
$

 
$
704,497














healthpeaklogohorizblkrgba01.jpg
23

Reconciliations
In thousands


For the year ended December 31, 2018
 
 
Senior Housing Triple-Net
 
SHOP
 
Life Science
 
Medical Office(1)
 
Other(1)
 
Corporate Non-segment
 
Total
Net income (loss)
 
$
191,105

 
$
76,168

 
$
961,071

 
$
155,799

 
$
78,357

 
$
(389,026
)
 
$
1,073,474

Interest income
 

 

 

 

 
(10,406
)
 

 
(10,406
)
Interest expense
 
2,404

 
2,725

 
316

 
474

 
1,469

 
258,955

 
266,343

Depreciation and amortization
 
79,605

 
104,405

 
140,480

 
200,430

 
24,579

 

 
549,499

General and administrative
 

 

 

 

 

 
96,702

 
96,702

Transaction costs
 

 

 

 

 

 
10,772

 
10,772

Loss (gain) on sales of real estate, net
 
(641
)
 
(93,977
)
 
(806,184
)
 
(4,428
)
 
(20,755
)
 

 
(925,985
)
Impairments (recoveries), net
 

 
44,343

 
7,639

 

 
3,278

 

 
55,260

Other expense (income), net
 

 

 

 

 
(9,605
)
 
(3,711
)
 
(13,316
)
Loss on debt extinguishments
 

 

 

 

 

 
44,162

 
44,162

Income tax expense (benefit)
 

 

 

 

 

 
(17,854
)
 
(17,854
)
Equity loss (income) from unconsolidated JVs
 

 

 

 

 
2,594

 

 
2,594

NOI
 
$
272,473

 
$
133,664

 
$
303,322

 
$
352,275

 
$
69,511

 
$

 
$
1,131,245

Adjustment to NOI
 
2,127

 
2,875

 
(9,589
)
 
(6,690
)
 
(627
)
 

 
(11,904
)
Cash NOI
 
$
274,600

 
$
136,539

 
$
293,733

 
$
345,585

 
$
68,884

 
$

 
$
1,119,341

Interest income
 

 

 

 

 
10,406

 

 
10,406

Share of unconsolidated JVs
 

 

 

 

 
64,906

 

 
64,906

Portfolio Income
 
$
274,600

 
$
136,539

 
$
293,733

 
$
345,585

 
$
144,196

 
$

 
$
1,194,653

Interest income
 

 

 

 

 
(10,406
)
 

 
(10,406
)
Share of unconsolidated JVs
 

 

 

 

 
(64,906
)
 

 
(64,906
)
Adjustment to NOI
 
(2,127
)
 
(2,875
)
 
9,589

 
6,690

 
627

 

 
11,904

Non-SPP NOI
 
(186,855
)
 
(102,813
)
 
(91,343
)
 
(44,854
)
 
(21,127
)
 

 
(446,992
)
SPP NOI
 
$
85,618

 
$
30,851

 
$
211,979

 
$
307,421

 
$
48,384

 
$

 
$
684,253

Non-cash adjustment to SPP NOI
 
1,180

 
1,835

 
(2,835
)
 
(5,681
)
 
673

 

 
(4,828
)
SPP cash NOI
 
$
86,798

 
$
32,686

 
$
209,144

 
$
301,740

 
$
49,057

 
$

 
$
679,425

___________________________________
(1)
During the year ended December 31, 2019, two facilities were reclassified from the other non-reportable segments to the medical office segment. Accordingly, all prior year segment information has been recast to conform to the current year presentation.


healthpeaklogohorizblkrgba01.jpg
24

Reconciliations
In thousands


Pro forma Portfolio Income(1)
 
 
Three Months Ended December 31, 2019
 
 
Senior Housing Triple-net
 
SHOP
 
Life Science
 
Medical Office
 
Other
 
Total
Portfolio Income(2)
 
$
39,715

 
$
44,749

 
$
84,714

 
$
91,531

 
$
36,560

 
$
297,269

Pro forma Adjustments:
 
 
 
 
 
 
 
 
 
 
 
 
Senior housing asset sales and transitions(3)
 
(19,195
)
 
(2,461
)
 

 

 
14,283

 
(7,374
)
Other pro forma adjustments(4)
 

 

 
2,030

 
(697
)
 
622

 
1,955

Pro forma Portfolio Income
 
$
20,519

 
$
42,288

 
$
86,743

 
$
90,834

 
$
51,465

 
$
291,850

 ______________________________________
(1)
Does not foot due to rounding and adjustments made to the Supplemental Report.
(2)
See pages 19 to 22 of this document for a reconciliation of Portfolio Income to net income.
(3)
Includes pro forma adjustments to reflect asset sales and asset transitions from senior housing triple-net to SHOP in connection with the Master Transactions and Cooperation Agreement with Brookdale Senior Living Inc., the Senior Housing Joint Venture, and certain other previously announced sales and transitions.
(4)
Pro forma to reflect the sale of our U.K. holdings and certain previously announced sales. Pro forma Portfolio Income is further adjusted to reflect acquisitions, dispositions, and other operator transitions as if they occurred on the first day of the quarter.

healthpeaklogohorizblkrgba01.jpg
25

Reconciliations
In thousands, except per month data

REVPOR SHOP(1)
 
 
Three Months Ended
 
 
December 31,
2018
 
March 31,
2019
 
June 30,
2019
 
September 30,
2019
 
December 31,
2019
REVPOR SHOP
 
 
 
 
 
 
 
 
 
 
Real Estate Revenues
 
$
127,909

 
$
126,181

 
$
177,001

 
$
212,275

 
$
209,714

Adjustments to real estate revenues
 
41

 
968

 
1,128

 
957

 
258

Cash Real Estate Revenues
 
$
127,950

 
$
127,149

 
$
178,129

 
$
213,232

 
$
209,972

Other adjustments to REVPOR SHOP(2)
 
(28,998
)
 
(21,714
)
 
(31,002
)
 
(28,094
)
 
(76,517
)
REVPOR SHOP revenues
 
$
98,952

 
$
105,436

 
$
147,127

 
$
185,138

 
$
133,455

 
 
 
 
 
 
 
 
 
 
 
Average occupied units/month
 
7,745

 
7,664

 
9,955

 
11,579

 
7,304

REVPOR SHOP per month(3)
 
$
4,259

 
$
4,586

 
$
4,927

 
$
5,330

 
$
6,091

 
 
 
 
 
 
 
 
 
 
 
SPP REVPOR SHOP
 
 
 
 
 
 
 
 
 
 
REVPOR SHOP revenues
 
$
98,952

 
$
105,436

 
$
147,127

 
$
185,138

 
$
133,455

Change in reporting structure(4)
 

 
(7,935
)
 
(37,036
)
 
(65,453
)
 
(65,578
)
Other non-SPP cash real estate revenues
 
(58,801
)
 
(56,070
)
 
(68,567
)
 
(77,907
)
 
(26,619
)
SPP REVPOR SHOP revenues
 
$
40,150

 
$
41,430

 
$
41,524

 
$
41,778

 
$
41,257

 
 
 
 
 
 
 
 
 
 
 
SPP average occupied units/month
 
2,889

 
2,882

 
2,902

 
2,947

 
2,942

SPP REVPOR SHOP per month(3)
 
$
4,633

 
$
4,792

 
$
4,769

 
$
4,725

 
$
4,675

 ______________________________________
(1)
Does not foot due to rounding and adjustments made to the Supplemental Report.
(2)
Includes revenue for newly completed facilities under lease-up, facilities sold or held for sale, facilities acquired or transitioned to new operators during the relevant period, and assets in redevelopment.
(3)
Represents the current quarter REVPOR divided by a factor of three.
(4)
Represents revenues for assets that transitioned from senior housing triple-net to SHOP during the year-over-year comparison period.


healthpeaklogohorizblkrgba01.jpg
26